In fact, in a specific experiment to evaluate the syndecan-1 cleavage, previous study showed the increase of syndecan-1 cleavage in PMA-stimulated GAC myeloma cells compared with DMSO treatment, which was also enhanced or decreased, respectively, after Heparinase III and inhibitor (BB-94) treatments [19]. The gene discussed is SDC1; the disease is plasma cell myeloma.